Dynavax Technologies: COVID-19 Partnership And Heplisav-B Progress Reveal Signs Of Life [Seeking Alpha]
Dynavax Technologies Corporation (DVAX)
Last dynavax technologies corporation earnings: 3/11 04:10 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.dynavax.com
Company Research
Source: Seeking Alpha
SummaryDynavax can only be described as a highly risky investment opportunity owing to the company's very mixed fortunes.In November 2017, at the third attempt, Dynavax secured approval for Heplisav-B, a Hepatitis B vaccine with best-in-class potential. The vaccine made sales of $34.6m in 2019.Dynavax made losses of $156m and $159m in 2018 and 2019 respectively and has now shelved its immuno-oncology business, laying off 38% of its staff and losing its CEO and CSO.Dynavax's share price hit an all-time low of $2.2 in mid-March but has since climbed on news the company has signed several collaboration agreements with agencies and companies to treat COVID-19.Dynavax's new management will need to prove they can hit or exceed analyst sales forecasts for Heplisav-B of $300m - if they can the share price ought to rise significantly.Investment ThesisSince joining the Nasdaq in 2005 Dynavax (DVAXTradingViewDynavax shares have lost 83% of their value since September 2015, falling from a price o
Show less
Read more
Impact Snapshot
Event Time:
DVAX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DVAX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DVAX alerts
High impacting Dynavax Technologies Corporation news events
Weekly update
A roundup of the hottest topics
DVAX
News
- CDC vaccine panel set to debate hepatitis b shots, childhood immunizations [Seeking Alpha]Seeking Alpha
- Dynavax to Participate at the 8th Annual Evercore Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Dynavax to Participate at the 8th Annual Evercore Healthcare ConferencePR Newswire
- Vaxart Inc (VXRT) Q3 2025 Earnings Call Highlights: Strategic Partnership and Revenue Surge ... [Yahoo! Finance]Yahoo! Finance
- Vaxart extends cash runway into Q2 2027 with Dynavax partnership and targets 2026 data readouts [Seeking Alpha]Seeking Alpha
DVAX
Earnings
- 11/5/25 - Beat
DVAX
Sec Filings
- 11/5/25 - Form 10-Q
- 11/5/25 - Form 8-K
- 10/16/25 - Form 8-K
- DVAX's page on the SEC website